



Building College-University
Partnerships for Nanotechnology
Workforce Development

Nanoparticles for Biological Applications Including Liposomes: Biocompatibility and Cellular Overview Part 3

Outline

- Biocompatibility
- Quick overview of cellular interaction
 - Scale, size, generic animal cell
- Nanoscale materials for biological interaction
 - Liposomes
 - Metal Nanoparticles
 - Nanoshells
 - Examples of bionano applications


Nanoparticles

- Nanoparticles are useful due to the small size and scaling to biology
- Nanoparticles made from a metal, semiconductor or polymer must interact on the cellular level. Some terms will be defined to understand this interaction
- Size and scale are important to understanding how nanotechnology can be applied to medicine
- On the cellular level, a cell is about 10 microns, and pores may be 100 nm, and an amino acid is about 1 nm


Nanoparticles-Liposomes

- The first man made nanoparticle we will look at is the liposome
- The word liposome is from two Greek words: lipo, "fat" and soma, "body". Phospholipids are the building block
- Phospholipids in an aqueous environment orient themselves in a thermodynamically stable form called a bilayer. This bilayer can further orient itself into a sphere known as a liposome
- So a liposome is an artificially-prepared vesicle composed of a lipid bilayer. The liposome can be used as a vehicle for administration of pharmaceutical drugs, DNA/RNA, tags, and nutrients. Liposomes are biodegradable

Nanoparticles-Liposomes



Phospholipid Structure



Nanoparticles-Liposomes




Illustration by Shannon McArdel

Nanoparticles-Liposomes


- The FDA has set up guidelines to establish quality control of new therapies based on liposome technology. These chemistry, manufacturing and control guidelines are given in this document:
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pdf>
- The physicochemical properties of the liposome drug product are critical to ensuring drug product quality
- These manufacturing guidelines also reflect the interaction of liposomes and show variables that change the functionality of the man made particle

Nanoparticles-Liposomes

- The FDA has proposed that properties specific to liposome drug products that may be useful to assess include:
 - morphology of the liposome, including lamellarity determination, if applicable
 - net charge
 - volume of entrapment in liposomal vesicles
 - particle size (mean and distribution profile)
 - phase transition temperature
 - spectroscopic data, as applicable
 - in vitro release of the drug substance from the liposome drug product
 - osmotic properties
 - light scattering index

Nanoparticles-Liposomes


- Liposomes can be used to deliver active molecules to the site of action, less waste and potential damage to other cells
- The major types of liposomes are the multilamellar vesicle (MLV), the small unilamellar vesicle (SUV), the large unilamellar vesicle (LUV)




Nanoparticles-Liposomes

- Sigma-Aldrich Liposome Kit: SKU L4395-1VL, Lipid mixtures for the preparation of liposomes Lyophilized powder. 85.00 USD
- Composition: Cholesterol, 9 μmol /package, L- α -Phosphatidylcholine (egg yolk), 63 μmol /package Stearylamine, 18 μmol /package
- <http://www.sigmaaldrich.com/catalog/product/sigma/l4395?lang=en®ion=US>
- <http://www.sigmaaldrich.com/catalog/product/sigma/l4395?lang=en®ion=US>


Nanoparticles-Liposomes




Nanoparticles-Liposomes



Nanoparticles-Liposomes



Nanoparticles-Liposomes



Nanoparticles-Liposomes

- Small unilamellar liposomes can hold a large payload, and suits many applications
- Generally 20 – 100 nm in diameter
- Liposomes can incorporate both water and fat soluble drugs or nutrients
- First-generation liposomes did not use a protective layer that would prevent degradation. Second-generation liposomes use an additional layer of material to “hide” the liposome from breakdown. Stealth liposomes.

Liposome Uses

- This “stealth” allows the liposome to survive in the body longer, and hopefully deliver the medicine to the desired area. Long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle
- Different methods have been suggested to achieve long circulation of liposomes in vivo, including coating the liposome surface with inert, biocompatible polymers
- A protective layer over the liposome surface and slows down liposome recognition by opsonins and therefore subsequent clearance of liposomes. Spleen and liver still filter
- One of the most common coatings is PolyEthylene Glycol (PEG)

Nanoparticles-Liposomes

- PEGylation is the process of covalent attachment of polyethylene glycol polymer chains to another molecule, normally a drug or therapeutic protein
- The covalent attachment of PEG to a drug or therapeutic protein can "mask" the agent from the host's immune system
- The PEG coating reduces uptake of the liposome within the ReticuloEndothelial System (RES) and therefore slows the rate of removal of the liposomes from the blood

Nanoparticles-Liposomes

- This effectively increases the biological half-life of the liposome; in clinical studies conventional liposomes have been shown to have a half-life of 20 min in body fluids, whereas PEG-liposomes can have a half-life of up to 5 days. Doxil, a liposome cancer drug has a half life of 2 days
- This circulation time is very critical
- Ligands can be attached directly to the liposome shell. It has been found that antibodies tethered to the arms of the polyethylene glycol are more effective for attachment to specific receptors

Nanoparticles-Liposomes Uses

- Liposomes can also be used to house tagging molecules. This tagging can be done inside the liposome and/or in the lipid shell of the bilayer, or on polymers bonded to the liposome shell
- Liposomes can be used to encapsulate and deliver drugs, DNA or RNA, tags, or nutrients for delivery to a specific cell

Nanoparticles-Liposomes Tagging


- QDs have been reported to be about 20 times brighter and 100 times more photostable in comparison with organic dyes such as rhodamine
- Utilizing a 50 nm QD, and a liposome of 300 nm, incorporation of the QD is possible
- Given these dimensions, 3 quantum dots were embedded in each liposome, and the resulting signal was the same as 3 free quantum dots. The authors proposed smaller QDs to incorporate into the liposome

Nanoparticles-Liposomes

Tagging

- This visual tagging can allow a surgeon to isolate diseased tissue from healthy tissue
- Liposomes can also incorporate plasmons or radioactive markers
- We will be looking at the liposome based cancer drug Doxil. It is interesting that gamma isotopes were used to track the effectiveness during drug trials. Results looked much like a PET scan

Gamma Scan of Kaposi's Sarcoma Patient




4hours

24hours

48hours

96hours

Doxorubicin in KS Lesions and Normal Skin (Biopsy at 48 Hrs. after Doxil)



Nanoparticles-Liposomes

Cancer Drug

- As seen in the last slide, liposomes have a “natural ability” (size) to target cancer
- In non cancerous samples the endothelial wall of all healthy human blood vessels are encapsulated by endothelial cells that are bound together by tight junctions. These tight junctions stop any particles in the blood from leaking out of the vessel. So healthy tissue will keep out small particles
- Tumor vessels do not contain the same level of seal between cells and are diagnostically "leaky". This ability is known as the Enhanced Permeability and Retention (EPR) effect. So tumors are like Swiss cheese, and small particles can leak into these defects

Nanoparticles-Liposomes


Cancer Drug

- Liposomes of certain sizes, typically less than 100 nm, can rapidly enter tumor sites from the blood, but are kept in the bloodstream by the endothelial wall in healthy tissue vasculature. Anti-cancer drugs such as Doxorubicin (Doxil), Camptothecin and Daunorubicin (Daunoxome) are currently being marketed in liposome delivery systems and take advantage of the leaky tissue to selectively deliver the drug
- Tumor tissues also usually lack effective lymphatic drainage, so they retain the drug. All of these factors lead to abnormal molecular and fluid transport dynamics, especially for macromolecular drugs. So tumors do not readily extract foreign material
- So the key to Doxil is long circulatory lifetime provided by the PEG coating, and specific size uptake by the leaky tumor from the EPR effect. So Doxil uses passive targeting

Nanoparticles-Liposomes

Cancer Drug

- Doxil



Nanoparticles-Liposomes

Cancer Drug

- So what is the role of Doxil? (Myocet, or Caelyx)
- Frank Szoka Ph.D founder of Sequest the company that invented Doxil and currently a member of the UCSF School of Pharmacy
- The goal of many cancer drugs is to kill the tumor faster than the rest of the patient. So selectivity is very important
- Doxil houses a “poison” called doxorubicin, known as red death
- Doxorubicin is an anthracycline, it works by intercalating DNA, with the most serious adverse effect being life-threatening heart damage. This treatment inhibits DNA replication in rapidly growing cancer cells. Doxorubicin is produced naturally by *Streptomyces peucetius*, a species of actinobacteria

Nanoparticles-Liposomes

Cancer Drug

- Anthracyclines are among the most effective anticancer treatments ever developed and are effective against more types of cancer than any other class of chemotherapeutic agents
- But daunorubicin is deadly to both the tumor and the heart
- Naturally the goal is to direct the poison to the tumor, and prevent interaction with the heart and other non target tissue
- As discussed, this selectivity is carried out with the use of the liposome that protects the heart, and at the same time shows preference to the tumor

Nanoparticles-Liposomes

Cancer Drug


- DaunoXome® (daunorubicin citrate liposome injection) is a prescription medicine, which belongs to a class of drugs known as anthracyclines. Anthracyclines are used to treat many types of cancer and work by interfering with the production of DNA, or genetic makeup, of the cancer cells, preventing them from multiplying. Since its US launch in 1996, thousands of patients have been treated with DaunoXome® worldwide
- DaunoXome® has a different delivery system compared to conventional anthracyclines. In DaunoXome®, the molecules of the drug are enclosed in a protective coating, known as a liposome. This protective coating allows the drug to remain in the body for longer, so that more of the treatment is delivered to cancer cells

Nanoparticles-Liposomes

Cancer Drug

- DaunoXome

This represents the aqueous core that contains daunorubicin citrate.



The diameter of the liposomes in DaunoXome is between 35 and 65 nm.



represents a molecule of DSPC.

Nanoparticles-Liposomes

Cancer Drug

- DaunoXome® was the first cancer product based on liposomes
- DaunoXome® also uses a PEG enhanced surface for long circulation time. These long circulating liposomes found to target tumor tissue by a mechanism known as enhanced permeation and retention
- Again, EPR is the property by which certain sizes of molecules (typically liposomes, nanoparticles, and macromolecular drugs) tend to accumulate in tumor tissue much more than they do in normal tissues

Nanoparticles-Liposomes

Cancer Drug

- Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects; a liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs
- Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. This inhibits rapidly growing cancer cells
- So the liposome passively targets the tumor, not other cells. Coatings on the liposome keep it active in the blood stream longer so it can be filtered/trapped in the tumor


List of clinically approved liposomal drugs

Name	Trade name	Company	Indication
Liposomal amphotericin B	Abelcet	Enzon	Fungal infections
Liposomal amphotericin B	Ambisome	Gilead Sciences	Fungal and protozoal infections
Liposomal cytarabine	Depocyt	Pacira (formerly SkyePharma)	Malignant lymphomatous meningitis
Liposomal daunorubicin	DaunoXome	Gilead Sciences	HIV-related Kaposi's sarcoma
Liposomal doxorubicin	Myocet	Zeneus	Combination therapy with cyclophosphamide in metastatic breast cancer
Liposomal IRIV vaccine	Epaxal	Berna Biotech	Hepatitis A
Liposomal IRIV vaccine	Inflexal V	Berna Biotech	Influenza
Liposomal morphine	DepoDur	SkyePharma , Endo	Postsurgical analgesia
Liposomal verteporfin	Visudyne	QLT, Novartis	Age-related macular degeneration, pathologic myopia, ocular histoplasmosis
Liposome-PEG doxorubicin	Doxil/Caelyx	Ortho Biotech , Schering-Plough	HIV-related Kaposi's sarcoma, metastatic breast cancer, metastatic ovarian cancer
Micellular estradiol	Estrasorb	Novavax	Menopausal therapy

Nanoparticles-Liposomes Genes

In Vivo Gene Therapy



In vivo gene therapy involves introduction of therapeutic DNA directly into the patient's body. The DNA is introduced by cell-specific direct injection into tissue in need. DNA in the form of a plasmid vector is introduced by a dermal vaccination. Modified liposomes are not currently used for gene therapy, but they will likely be the next advancement in therapeutic gene delivery as cell-specific receptor-mediated DNA carriers. Once inside the body and in contact with the specifically targeted cells, the inserted DNA is incorporated into the tissue's cells where it encodes the production of the needed protein.




<http://genomics.energy.gov/>

Nanoparticles-Liposomes Genes

**Unilamellar vesicle with
entrapped nucleic acid**



**Cell membrane
destabilization
and lipid fusion**



Cytoplasm



Nanoparticles-Liposomes

Nutrition

- Nutritional supplement companies are currently encapsulating nutrients such as vitamin C in liposomes
- Liposome delivery increases the bioavailability of nutrients compared to traditional oral dietary capsules
- Liposomes bypass the destructive elements of the gastric system and aid the encapsulated nutrient to be delivered to the cells and tissues
- Hydrophilic drugs/nutrients/tags can be trapped in the central aqueous core of the liposomes, and lipophilic drugs can be solubilized within the lipid bilayer